A study published in the New England Journal of Medicine has found beta carotinene (beta-C) can reduce blood cholesterol levels in people with type 2 diabetes and improve heart health.
The findings are a significant advancement over previous studies that suggested beta-C reduced blood cholesterol in people who had type 2.
The research team is the first to suggest beta-carotene is effective against type 2, and it suggests it may be effective against all forms of type 2 that require insulin to function.
A key limitation of the study was that people with diabetes who took beta-Carotene were given beta-blockers for their diabetes.
The study found the beta-A beta-carboline beta-PEA beta-D-aspartate, which is commonly used to treat diabetes, could not be used in this trial.
The authors also found beta-B-carotinene and beta-FAs, which are naturally present in the body, could reduce the risk of developing diabetes.
This finding is significant, because it suggests beta-CARB is a promising new treatment that may be used to reduce blood levels of cholesterol and other factors that could contribute to the development of type 1 diabetes.
Beta-Carotinene can be found in the natural products used by people who use beta-Blockers, such as kiwifruit, blueberries, blueberry juice and apple juice.
These products are also a source of beta- Carotene and its precursor, beta-HCO3-carbinol.
The beta- CARB beta-Glycine can be produced from beta-Tocopherol in the human body.
The carotenes and beta carolinoids are naturally found in many plant foods.
In the study, the researchers looked at a small cohort of people with the following types of diabetes: Type 2, Type 3, Type 4, Type 5, Type 6 and Type 7.
Those who took the beta blocker were less likely to develop type 2 than those who did not take the beta blockers.
Beta Carotenes can lower blood levels in those with type 1, but are not known to reduce levels of blood cholesterol or heart disease in people without type 1.
The researchers also found that beta-L-carobic acid can reduce levels in blood, but its effects were not significant in people taking beta- blocker.
The team hopes to investigate the potential of beta carolines in the treatment of type 3 diabetes.
They are currently in the clinical trials phase of this study, which began in September and will last until the end of the year.
“The beta carobins can significantly reduce blood glucose levels in the presence of insulin and may reduce the development or progression of type II diabetes,” said lead author Elizabeth A. Smith, PhD, of the University of Illinois at Chicago.
“However, this is not a complete and comprehensive study and further research is needed to better understand the clinical benefits of beta CARB for people with this type of diabetes.”
The research was funded by the National Institutes of Health.